Those with IHC scores of 2+ would be further tested to ultimately determine HER2 status. 2 An IHC score shapes a patient’s entire course of treatment so it’s critical for patients to know ...

-- a pun on hairs. But splitting is because the new drugs, the ADC [antibody-drug conjugate] trastuzumab deruxtecan [Enhertu], is indicated for patients that have HER2 1+ or 2+ IHC, but not HER2 0.

The highest response rates continued to be seen in the exploratory analysis of patients with tumor HER2 expression of immunohistochemistry (IHC) 3+ (n=75) as confirmed by central testing, where ...

– HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during ...

Locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen ...

In the HER2-low population, findings showed treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy (hazard ratio [HR], 0.62 [95% ...

But based on some of these clinical trials, they were considered HER2-low, meaning there was HER2 expression assessed by IHC at low levels, 1+ or 2+, even though there was no gene amplification.

Figure 2-2: Classification of HER2 expression in breast cancer by IHC. Source: Agostinetto E, Curigliano G, Piccart M. Emerging treatments in HER2-positive advanced breast cancer: Keep raising the ...

HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of many types of tumors.11 HER2 expression (IHC 3+/ 2+) is present in 18% to 56% of endometrial cancers and is ...

Locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen ...

In patients with HER2-ultralow expression, trastuzumab deruxtecan reduced the risk of disease progression or death by 22% compared with chemotherapy (HR, 0.78 [95% CI, 0.50-1.21); median PFS was ...

Approximately 70% of diagnosed cases are considered what has been historically called HR-positive, HER2-negative breast cancer (measured as HER2 score of IHC 0, IHC 1+ or IHC 2+/ISH-). 3 Endocrine ...